Autoimmune disease drug gets extended safety check
NCT ID NCT06203457
Summary
This study followed 24 adults with primary Sjögren's syndrome to check the long-term safety of a drug called efgartigimod. All participants had already finished a previous study with the same drug and continued treatment without interruption. The main goal was to monitor for side effects over 48 weeks while also tracking symptoms and disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centrum Medyczne Plejady
Krakow, 30 363, Poland
-
Centrum Medyczne Pratia Poznan
Skorzewo, 60 185, Poland
-
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.
Poznan, 60-848, Poland
-
Debreceni Egyetem
Debrecen, 4032, Hungary
-
FutureMeds sp zoo
Wroclaw, 50 088, Poland
-
Klinika Reuma Park Sp zoo Sp K
Warsaw, 02 665, Poland
-
MCBK SC
Grodzisk Mazowiecki, 05 825, Poland
-
MICS Centrum Medyczne Warszawa
Warsaw, 00 874, Poland
-
Narodowy Instytut Geriatrii
Warsaw, 02637, Poland
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Vita Verum Medical Egeszsegugyi Szolgaltato Bt.
Székesfehérvár, 8000, Hungary
Conditions
Explore the condition pages connected to this study.